RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Novo Nordisk A/S ROE 2024

Novo Nordisk A/S ROE

0.79

Novo Nordisk A/S Dividend yield

1.61 %

Ticker

NOVO B.CO

ISIN

DK0060534915

WKN

A1XA8R

In 2024, Novo Nordisk A/S's return on equity (ROE) was 0.79, a 18.08% increase from the 0.67 ROE in the previous year.

Novo Nordisk A/S Aktienanalyse

What does Novo Nordisk A/S do?

Novo Nordisk A/S is a Danish company specializing in the production of insulin and other diabetes medications. It was founded in 1923 and has its headquarters in Bagsværd, Denmark. Novo Nordisk is the world's largest manufacturer of insulin and one of the key players in the field of diabetes treatment. Novo Nordisk A/S ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Novo Nordisk A/S's Return on Equity (ROE)

Novo Nordisk A/S's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Novo Nordisk A/S's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Novo Nordisk A/S's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Novo Nordisk A/S’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Novo Nordisk A/S Stock

What is the ROE (Return on Equity) of Novo Nordisk A/S this year?

The ROE of Novo Nordisk A/S this year is 0.79 undefined.

How has the Return on Equity (ROE) of Novo Nordisk A/S developed compared to the previous year?

The ROE of Novo Nordisk A/S has increased by 18.08% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Novo Nordisk A/S?

A high ROE indicates that Novo Nordisk A/S generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Novo Nordisk A/S?

A low ROE can indicate that Novo Nordisk A/S is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Novo Nordisk A/S affect the company?

A change in ROE (Return on Equity) of Novo Nordisk A/S can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Novo Nordisk A/S?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Novo Nordisk A/S?

Some factors that can influence Novo Nordisk A/S's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Novo Nordisk A/S pay?

Over the past 12 months, Novo Nordisk A/S paid a dividend of 14.15 DKK . This corresponds to a dividend yield of about 1.61 %. For the coming 12 months, Novo Nordisk A/S is expected to pay a dividend of 14.94 DKK.

What is the dividend yield of Novo Nordisk A/S?

The current dividend yield of Novo Nordisk A/S is 1.61 %.

When does Novo Nordisk A/S pay dividends?

Novo Nordisk A/S pays a quarterly dividend. This is distributed in the months of September, April, September, April.

How secure is the dividend of Novo Nordisk A/S?

Novo Nordisk A/S paid dividends every year for the past 26 years.

What is the dividend of Novo Nordisk A/S?

For the upcoming 12 months, dividends amounting to 14.94 DKK are expected. This corresponds to a dividend yield of 1.7 %.

In which sector is Novo Nordisk A/S located?

Novo Nordisk A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Novo Nordisk A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Novo Nordisk A/S from 3/26/2024 amounting to 6.4 DKK, you needed to have the stock in your portfolio before the ex-date on 3/22/2024.

When did Novo Nordisk A/S pay the last dividend?

The last dividend was paid out on 3/26/2024.

What was the dividend of Novo Nordisk A/S in the year 2023?

In the year 2023, Novo Nordisk A/S distributed 11.15 DKK as dividends.

In which currency does Novo Nordisk A/S pay out the dividend?

The dividends of Novo Nordisk A/S are distributed in DKK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Novo Nordisk A/S stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Novo Nordisk A/S

Our stock analysis for Novo Nordisk A/S Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novo Nordisk A/S Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.